VIDEO: Timber Pharmaceuticals’ topical isotretinoin shows promise in congenital ichthyosis

BOSTON — Timber Pharmaceuticals Chief Medical Officer Alan Mendelsohn, MD, discusses the company’s topical drug candidate for the treatment of congenital ichthyosis at the American Academy of Dermatology Annual Meeting.

Timber recently concluded an end-of-phase 2 meeting with the FDA regarding TMB-001 0.05% (topical isotretinoin) and will initiate a phase 3 trial program, the company announced in a press release.

Reference:

• Timber Pharmaceuticals announces positive end-of-phase 2 meeting with FDA for TMB-001 in moderate to severe congenital ichthyosis. https://www.globenewswire.com/en/news-release/2022/02/03/2378451/0/en/Timber-Pharmaceuticals-Announces-Positive-End-of-Phase-2-Meeting-with-FDA-for-TMB-001-in-Moderate-to-Severe-Congenital-Ichthyosis.html. Published Feb. 3, 2022. Accessed March 28, 2022.